The blood hormone erythropoietin (EPO), upon binding to its receptor (EpoR), modulates high 24 fat-diet (HFD)-induced obesity in mice, improves glucose tolerance, and prevents white adipose 25 tissue inflammation. Transgenic mice with constitutive over-expression of human EPO solely in 26 brain (Tg21) were used to assess the neuro-endocrine EPO effect without increasing the 27 hematocrit. Male Tg21-mice resisted HFD-induced weight gain, showed lower serum ACTH, 28 corticosterone and C-reactive protein levels, and prevented myeloid cell recruitment to 29 hypothalamus compared with WT-males. HFD-induced hypothalamic inflammation (HI) and 30 microglial activation were higher in male mice, and Tg21-males exhibited lower increase in HI 31 than WT-males. Physiological EPO function in the brain also showed sexual dimorphism in 32 regulating HFD response. Targeted deletion of EpoR gene expression in neuronal and glial cells 33 worsened HFD-induced glucose intolerance in both male and female mice, but increased weight 34 gain and HI in the hypothalamus in male mice only. Female estrogen production blocked 35 reduced weight gain and HI. Both male and female Tg21-mice kept on normal-chow and HFD 36 showed significantly improved glycemic control. Our data indicates that cerebral EPO regulates 37 weight gain and HI in a sex-dependent response, distinct from EPO regulation of glycemic 38 control, and independent of erythropoietic EPO response. 39 40 41 42 43 44 45 3 Introduction: 46
Abstract: 23
The blood hormone erythropoietin (EPO), upon binding to its receptor (EpoR), modulates high 24 fat-diet (HFD)-induced obesity in mice, improves glucose tolerance, and prevents white adipose 25 tissue inflammation. Transgenic mice with constitutive over-expression of human EPO solely in 26 brain (Tg21) were used to assess the neuro-endocrine EPO effect without increasing the 27 hematocrit. Male Tg21-mice resisted HFD-induced weight gain, showed lower serum ACTH, 28 corticosterone and C-reactive protein levels, and prevented myeloid cell recruitment to 29 hypothalamus compared with WT-males. HFD-induced hypothalamic inflammation (HI) and 30 microglial activation were higher in male mice, and Tg21-males exhibited lower increase in HI 31 than WT-males. Physiological EPO function in the brain also showed sexual dimorphism in 32 regulating HFD response. Targeted deletion of EpoR gene expression in neuronal and glial cells 33 worsened HFD-induced glucose intolerance in both male and female mice, but increased weight 34 gain and HI in the hypothalamus in male mice only. Female estrogen production blocked 35 reduced weight gain and HI. Both male and female Tg21-mice kept on normal-chow and HFD 36 showed significantly improved glycemic control. Our data indicates that cerebral EPO regulates 37 weight gain and HI in a sex-dependent response, distinct from EPO regulation of glycemic 38 control, and independent of erythropoietic EPO response. DIO is associated with chronic low-grade hypothalamus inflammation that occurs within 116 the first few days after HFD-feeding, induces hypothalamic activation of microglial cells and 117 increases pro-inflammatory cytokines (27) . Accordingly, we quantified inflammatory cytokine 118 marker TNF, microglial cell marker Iba1, and activated microglial cell marker CD68, to assess 119 EPO regulated response in the mediobasal hypothalamus (MBH) of male mice. On NCD, the 120 numbers of TNF + cells were very scarce but more pronounced in WT-than Tg21-males ( Figure  121 2A and 2C). On HFD-feeding the numbers increased in both WT-and Tg21-males and become 122 3-fold higher in WT-than Tg21-animals ( Figure 2B and 2C) . Similarly, the number of microglial 123 cells was higher in WT-mice on NCD (Figure 2A and 2D ). With DIO, Iba1 + cells increased in 124 both WT-and Tg21-mice and becoming 2-fold higher in WT-than Tg21-mice ( Figure 2B and 125 2D). Quantification of Iba1 + staining also showed higher staining density in WT mice vs Tg21 126 mice ( Figure 2E and 2F ). CD68, a marker for activated microglial cells, was also more abundant 127 in MBH region of HFD-fed WT mice than HFD-fed Tg21 mice ( Figures 2G, 2H ). Moreover, 128 during DIO, expression of three additionally analyzed inflammatory genes (Ccl2, Il6, and Il1) 129 increased markedly in hypothalamus of WT-males with little or no change in Tg21-130 hypothalamus ( Figure 2I ). Importantly, these changes in hypothalamus inflammation are 131 sexually dimorphic as in female WT-and Tg21-mice, TNF + and Iba1 + cell numbers were very 132 low during NCD with comparable increases on HFD-feeding, and no significant difference in 133 hypothalamus Ccl2, Il6, and Il1 relative gene expression (supplementary figure 1). 134
As DIO induces rapid infiltration of blood-derived peripheral myeloid cells into the 135 hypothalamus (29), we assessed recruitment of peripheral myeloid cells into the MBH. P2Y12 is 136 7 a very specific marker for microglial cells and its expression is reduced in activated microglial 137 cells (30). During NCD, P2Y12 + cell number was moderately higher in male WT-mice (Figures 138 3A, 3C), while during DIO, these cells decreased in WT-mice but increased in Tg21-mice to 139 almost double the WT number ( Figures 3A, 3C ). CD169 is a marker for myeloid monocyte-140 derived cells recruited from the periphery and not expressed by resident microglial cells (31) . 141
Little or no CD169 + cells were detected during NCD and with development of DIO the number 142 of CD169 + cells increased in males, reaching 5-fold higher or more in WT-than Tg21-mice 143 Cerebral EPO expression in transgenic Tg21 mice is approximately 4-fold compared to 150 WT controls (28). To study if physiological EPO levels and signaling via EpoR in brain, 151 especially in neuronal cells, can regulate HFD-induced metabolic changes in mice, we knocked 152 out EpoR gene expression in neuronal cell precursors. This was achieved by mating chimeric 153
EpoR floxed mice with mice containing a cre-recombinase gene controlled by the nestin 154 promoter (32). Glial EpoR expression is expected to be unchanged. Ablation of EpoR gene 155 expression in nestin-cre;EpoR loxP/loxP mice was verified by mRNA quantification in brain, 156
comparing WT mice and nestin-cre;EpoR WT/WT mice, while its splenic expression as well as the 157 hematocrit levels were unaffected (supplementary figure 3) . For all subsequent studies with the 158 nestin-cre;EpoR loxP/loxP mice, the nestin-cre;EpoR WT/WT mice were used as control to counter the 159 8 off-target effects of nestin promoter driven cre-recombinase expression, and to ensure that the 160 metabolic effects were seen due to lack of EpoR gene and not due to nestin-cre transgene (33-161
35). 162
During DIO, male mice deficient for cerebral EpoR (e.g. nestin-cre;EpoR loxP/loxP ) gained 163 significantly more weight than the male control (nestin-cre;EpoR WT/WT ) ( Figure 4A ) and became 164 more glucose intolerant after 4 weeks of HFD feeding ( Figure 4B ). Conversely, females lacking 165 the cerebral EpoR showed a moderate but significantly more weight gain only after two weeks of 166 HFD feeding and not at other time points tested ( Figure 4C ). Nevertheless, like male mice, 167 glucose tolerance was worse in female cerebral EpoR-deficient mice compared to female 168 controls ( Figure 4D ). HFD-induced TNF expression in the MBH of male nestin-169 cre;EpoR loxP/loxP mice was also significantly higher than male nestin-cre;EpoR WT were recruited more in the hypothalamus of nestin-cre;EpoR loxP/loxP mice than nestin-175 cre;EpoR WT/WT mice, but P2Y12 + cells were not significantly different between the two groups 176 ( Figures 4K, 4L ). In summary, these studies show that similar to EPO over-expression, 177 endogenous physiological EPO/EpoR signaling in the brain plays an important role in preventing 178 HFD-induced weight gain and inflammation in male mice and can regulate glucose tolerance in 179 both male and female mice. The hypothalamus-pituitary-adrenal (HPA) axis is a critical neuroendocrine control over 183 stress response-induced during DIO. The hypothalamus and pituitary gland function to maintain 184 energy expenditure. Corticotropin releasing factor (CRF) released from the hypothalamus 185 induces ACTH secretion from the pituitary which in turn drives release of corticosterone from 186 the adrenal gland. ACTH level during NCD showed a small reduction in Tg21-mice that 187 increased in both WT-and Tg21-mice during DIO to become 1.7-fold greater in WT-than Tg21-188 mice ( Figure 5A ). Corticosterone levels were similar in WT-and Tg21-mice during NCD and 189 increased only in WT-mice during DIO becoming two-fold greater ( Figure 5B ). The 190 inflammatory marker C-reactive protein was higher in WT-than Tg21-mice during NCD, was 191 induced in DIO in both WT-and Tg21-mice, and remained significantly higher in WT-mice 192 ( Figure 5C ). This observation, too, was gender-specific, as in female WT-and Tg21-mice, no 193 differences were observed in serum levels of ACTH, corticosterone, and C-reactive protein 194 during NCD or HFD (data not shown). 195
196

Fgf21 and adiponectin levels during DIO 197
Female mice appear to be protected from hypothalamus inflammation and pituitary-198 adrenal activation, but like males, exhibit glucose intolerance during DIO. Fgf21, a cytokine 199 produced primarily in liver, is involved in regulation of glucose metabolism, and insulin 200 sensitivity, parameters that are improved in male and female Tg21-mice during NCD and DIO. 201
During NCD, Fgf21 is elevated in male and female Tg21-mice. However, after 1 and 3 months 202 on HFD, Fgf21 levels increase in male and female WT-mice beyond the levels in Tg21-mice, 203 that remain unchanged ( Figure 5D , 5E). Adipocytes are one main target of Fgf21 where Fgf21 204 promotes adiponectin production. During NCD, male and female Tg21-mice show significantly 205 higher adiponectin level, although fat mass was comparable to WT-mice ( Figure 5F , 5G and 206 Table 1 ). Adiponectin levels increased during HFD feeding in both Tg21 and WT-mice but with 207 a higher elevation in male and female Tg21-mice. This observation was surprising, as male WT-208 mice have more fat mass ( Figure 5F and Table 1 ) and suggests that during DIO, despite higher 209 Fgf21 in WT-mice ( Figure 5D , 5E), adiponectin levels were not concomitantly higher in these 210 mice. On the other hand, Tg21 males and females showed a greater sensitivity to Fgf21 as 211 reflected in adiponectin levels ( Figure 5F , 5G and Table 1) . 212 213 Klotho expression in WAT and Fgf21 signaling in hypothalamus during DIO
214
While systemic metabolic effects of Fgf21 are mediated mainly by adiponectin from 215 WAT (36), hepatic Fgf21 can regulate glycogen synthesis and ketone body production (37, 38). 216 Fgf21 can also cross the blood-brain barrier and act as a messenger between liver and 217 hypothalamus thereby regulating CRF expression and adrenal corticosterone levels (39). In the 218 presence of the critical co-receptor Klotho, Fgf21 binds to isoforms of the Fgf receptor 1, 2, 3, 219 and 4, leading to dimerization and auto-phosphorylation of the Fgf receptor followed by down-220 stream activation of extracellular mitogen activated protein kinase 1 and 2 (Erk1/2) to translocate 221 and activate specific transcription factors in the nucleus. Expression of Fgf receptors 1, 2, 3, and 222 4 was unchanged during NCD and after 3 months of HFD (data not shown), while Klotho 223 expression in WAT during DIO was significantly reduced in male and female WT-mice in 224 contrast to male and female Tg21-mice that showed no difference in Klotho expression in 225 WAT, liver, and hypothalamus during NCD or HFD ( Figures 6A, 6B , 6C). During DIO, Fgf21 in 226 serum is higher in male and female WT-mice ( Figure 5D , 5E), and on the other side of the blood-227 brain barrier we detected higher CRF hypothalamus expression in male WT-than Tg21-mice but 228 11 comparable in female mice ( Figure 6D, 6E ). This suggested that while Fgf21 increased in WT-229 mice during DIO, it did not lead to elevated adiponectin secretion possibly due to Klotho 230 downregulation in WT-WAT compared to Tg21-mice. Moreover, CRF secretion from 231 hypothalamus was higher in male WT-mice compared to male Tg21-mice but remained 232 unchanged in female mice. 233 234
Intracerebroventricular EPO administration during DIO prevents weight gain, lowers 235 blood glucose levels, and attenuates hypothalamic inflammation 236
To determine if administration of recombinant human EPO in brain is protective for DIO, 237 EPO at 10 U/day was infused continuously for 2 weeks into the lateral cerebral ventricle of male 238 mice, together with HFD-feeding. Saline infusion was used as control. EPO infusion reduced 239 cumulative weight gain and fat mass from days 7 through 14 of HFD-feeding with no significant 240 effect on in lean mass ( Figures 7A, 7B , 7C). EPO brain infusion resulted in a modest increase in 241 hematocrit at week 1 and a modest decrease at week 2 compared to saline infused mice ( Figure  242 7D). The hematocrit level in week 2 of EPO-infused mice was significantly lower than week 1, 243 which could possibly be due to a feedback from the brain through the sympathetic nervous 244 system (40). Fasting glucose levels were significantly lower in males receiving EPO brain 245 infusion ( Figure 7E ). Finally, at the end of two weeks of EPO infusion, hypothalamus expression 246 of inflammatory markers IL-1, IL-6, SOCS3, TNF were down regulated while expression of 247 anti-inflammatory marker IL-10 was increased ( Figure 7F ). These findings suggest that 248 pharmacological administration of EPO into brain during HFD-feeding can prevent weight gain 249 and hypothalamus inflammation and improve glucose tolerance. 250 251 12
EPO action in female Tg21-mice is blunted by estrogen's protective effect against DIO 252
Male mice are more susceptible to DIO than females (41) and obesity related 253 hypothalamic inflammation affects male but not females rodents (42-44). Similarly, microglial 254 cell response during HFD-feeding is sexually dimorphic with male mice presenting more 255 accumulation and activation of microglial cells in MBH (42). Moreover, metabolic response of 256 EPO protection from DIO is gender-specific and is observed predominantly in male mice (18) . 257
Here we found that inflammatory stress in female WT-and Tg21-hypothalamus is comparable 258 during HFD-feeding and EPO does not elicit additional protective effect against DIO in female 259 mice (supplementary figures 1 and 2). To assess the protective effect of estrogen in DIO, we 260 used ovariectomized (OVX) and sham controlled female mice undergoing a six weeks HFD 261 feeding period. Body weight gain and fat mass after three and six weeks was greatest in OVX-262 WT-mice ( Figure 8A , 8B), suggesting that estrogen plays a dominant role in preventing DIO in 263 female mice and estrogen reduction in ovariectomized mice results in significantly higher body 264 weight and fat mass gain during HFD-feeding. Furthermore, EPO over-expression in brain 265 protects against DIO in OVX-Tg21-mice with loss of estrogen protection, compared with OVX-266
WT-mice. 267
Assessment of direct inflammatory effects in MBH of WT-and Tg21-mice subjected to 268 ovariectomy and HFD-feeding showed that reduction of estrogen production in OVX-WT-mice 269 increased TNF + cells and Iba1 + cells in hypothalamic sections, indicating an increase in 270 inflammatory response and microglial cell number compared with sham WT-mice ( Figure 8C , 271 8D). In contrast, OVX-Tg21-mice with elevated brain EPO did not show any such increase 272 compared with sham-Tg21-mice ( Figure 8C , 8D). Female sham-WT-and sham-Tg21-mice did 273 not show any difference in TNF or Iba1 staining. These findings suggested that estrogen 274 13 protection for DIO includes concomitant reduced hypothalamic inflammation, and that loss of 275 estrogen production in ovariectomized female mice with HFD-feeding increases hypothalamic 276 inflammation. However, female OVX-Tg21-mice with elevated brain EPO do not exhibit 277 hypothalamus inflammatory response during HFD-feeding due to EPO anti-inflammatory effect 278 that is also seen in male mice with elevated brain EPO in Tg21-mice ( Figure 2 ) and in 279 intracerebroventricular EPO administration ( Figure 7) . 280 281
Discussion: 282
Hypothalamus plays a master role to coordinate food intake and energy expenditure, and 283 hormones like leptin and insulin act as messengers between the periphery and hypothalamus. 284
These hormones inform about peripheral energy stocks and trigger physiological responses in 285 hypothalamus controlling hunger, glucose metabolism, and thermogenesis. We previously found 286 that EPO treatment in WT-mice decreases body weight and fat mass by increasing energy 287 expenditure (12, 15) and can directly activate POMC expression by inducing STAT3 signaling 288 pathways after subcutaneous administration of recombinant human EPO at 3000 U/kg body 289 weight dose (13). Similarly, intraperitoneal administration of EPO at 5000 U/kg body weight has 290 been shown to be neuroprotective in rodent models of focal brain ischemia (45) and 291 schizophrenia (46). These studies show that EPO administered at such doses can cross the blood-292 brain barrier and elicit neuroprotective as well as metabolic effects. Similarly, endogenous 293 physiological EPO/EpoR signaling also regulates metabolism as mice lacking EpoR gene in non-294 hematopoietic tissues exhibit fat gain, glucose intolerance and insulin resistance resulting from 295 low energy expenditure that is primarily due to loss of endogenous EPO response in WAT and 296 hypothalamus (12). These mice presented with high plasma ACTH concentration due to higher 297 14 ACTH secretion from anterior pituitary (14). These non-erythropoietic EPO activities were 298 attributed to EPO response in multiple tissues including the brain. Here we focus on elucidating 299 EPO's brain-specific role that may contribute to metabolic response especially during DIO. As a 300 model with elevated brain EPO without increase in EPO stimulated erythropoiesis, we use Tg21-301 mice overexpressing EPO in brain and WT-mice with intracerebral ventricular EPO pumps. 302
Increased cerebral EPO levels prevent weight and fat gain during HFD-feeding in male mice and 303 male Tg21-mice exhibited higher energy expenditure. Absence of EpoR in brain and other non-304 hematopoietic cells leads to reduced locomotor activity and energy expenditure while EPO 305 treatment in WT-mice increased these parameters (12). Furthermore, elevated brain EPO in 306
Tg21-mice or in mice administered high dose EPO increased maximal aerobic capacity and time 307
to exhaustion during exercise (47) underlining the widespread impact of cerebral EPO on 308 physical energy expenditure. Intracerebroventricular administration of EPO has been previously 309
shown to be protective against cortical infarction, loss of thalamic neurons, behavioral deficits 310 and reperfusion injury in a rodent model of permanent middle cerebral artery occlusion (MCAO) 311 (48-50). Here, our findings show that such continuous EPO infusion can also be protective 312 against DIO, and related glucose intolerance, and hypothalamic inflammation. We detected a 313 small but significant decrease in hematocrit in EPO infused mice at week 2 which could possibly 314 be due to feedback regulation mediated by the high EPO levels in the brain (40). Previous studies 315 have shown that the sympathetic nervous system and its constituents, the sympathetic nerve 316 fibers and neural crest-derived cells are critical regulators of hematopoietic stem cells behavior 317 during homeostasis and stress (51-53). 318
We observed that in male Tg21-mice, reduced body weight gain and fat mass 319 accumulation was accompanied by improved glucose metabolism and insulin sensitivity during 320 both NCD and HFD-feeding. Interestingly, improved glycemic control in Tg21-mice were seen 321 in both male and female mice, possibly regulated by Fgf21 and adiponectin action. Fgf21 is a 322 hormone made primarily in the liver and acts as a key metabolic regulator essential for 323 maintaining glucose homeostasis (54). In mice, Fgf21 is induced at the transcriptional level and 324 released from liver in response to nutritional stresses like HFD-feeding (55). Similarly, in 325 humans, circulating FGF21 levels correlate positively with body mass index (BMI) (56), and 326 plasma FGF21 is elevated in obese and diabetic humans (57). This suggests that during obesity 327 inflammatory effect is accompanied with infiltration by bone marrow derived CD169 + myeloid 345 cells that is critical for causing "microgliosis" in MBH and metabolic dysfunction (63). To 346 disrupt EPO response in the brain, we targeted deletion of EpoR in nestin + cells including their 347 progeny that includes neurons but not microglial cells (64, 65). Our attempts at EpoR gene knock 348 out in all cell types by viral Cre administration in EpoR loxP/loxP mice resulted in non-specific 349 recombinase action even in WT mice. Therefore, the effects seen in Nestin-Cre:EpoR loxPloxP mice 350 could only be contributed by physiological EPO function in neuronal cells. Our findings in male 351
Tg21-mice and in male WT-mice with intracerebroventricular EPO infusion directly links EPO 352
protection and lower hypothalamus inflammation. In mouse WAT, peripheral EPO treatment 353 during DIO prevents WAT inflammation, reduces macrophage infiltration, and improves glucose 354 tolerance and insulin sensitivity (6). Male Tg21-mice have reduced levels of the inflammatory 355 marker C-reactive protein in serum, during both NCD and HFD-feeding, suggesting that 356 peripheral inflammation is also lower in Tg21-mice independent of weight and fat mass 357 difference. 358 EPO regulation of body weight/fat mass in female mice during HFD-feeding is minimal 359 but is readily apparent in ovariectomized mice, and is masked in ovariectomized mice with 360 estradiol supplementation (18). Our present studies were carried out in randomly cycling females 361 as random cycling better resembles a chronic condition such as DIO in cycling females. Also, 362 previous studies done in cycling female mice have not found any significant difference in 363 inflammatory cytokines throughout the estrous cycle (66), and the HPA axis response to 364 endotoxins does not vary with different stages of the normal estrous cycle (67). Moreover, 365
female mice have been shown to be resistant to hypothalamic inflammation and DIO through 366 estrogen effects and ovariectomy can eliminate these protective effects (41-43). Results from 367
female Tg21-mice also suggest that estrogen can elicit the maximal protective effect against 368 hypothalamic inflammation and DIO, and that EPO over-expression in brain is not additionally 369 beneficial in female mice. However, loss of estrogen as occurring in OVX-WT-mice results in 370 increased hypothalamic inflammation on HFD-feeding, and the protective effect of elevated 371 brain EPO for hypothalamic inflammation in DIO is demonstrated in OVX-Tg21-mice. An 372 impact of estrogen on EPO-regulated functions in the brain and carotid bodies has been already 373 postulated in the past using the same and similar EPO-overexpressing mouse models (68, 69). It 374 was shown that cerebral EPO mediates the neuronal control of the ventilatory response to 375 hypoxia in a sex-dependent manner and that estradiol interferes with EPO's impact on this 376 response (70). Taken together, all these findings strongly support the evidence that EPO and 377 estrogen may be functioning through similar mechanisms regulating metabolism and ventilation 378 both in the brain and in the periphery. The observations reported here might have a widespread clinical impact on future 386 therapies targeting anemia. So far, EPO and its derivatives have been used to enhance 387 erythropoiesis. EPO itself is controlled in an oxygen-dependent manner via the cellular oxygen 388 sensing axis HIF-2:PHD2 (75). At present, new inhibitors of PHD2 that in turn stabilize the -389 subunit of HIF-2 and subsequently increase transcription of the EPO gene (76), are in the process 390 of being commercialized. As these small compounds will most probably cross the blood-brain 391 barrier, it is conceivable that they will inhibit the PHD2 activity in neuronal cells too, ultimately 392 increasing cerebral EPO production. If so, elevated EPO levels in the brain might have an effect 393 on glucose metabolism and hypothalamic metabolism and inflammation as shown here. A 394 limitation of the current study is that the Tg21-mice being a chronic over-expression of human 395 EPO cDNA, can develop adaptive changes that could mask some potential neuroendocrine 396 effects of EPO during DIO. These can be further investigated by studying a conditional over-397 expression system which can eliminate the scope of any possible adaptive changes in Tg21 mice. 398
In summary, our studies demonstrate involvement of EPO/EpoR-signaling in brain and 399 particularly in the hypothalamus in metabolic regulation during NCD and DIO. EPO over-400 expression in brain improves glucose utilization in male and female mice, possibly through 401 response. This also parallels EPO regulation of weight and fat gain that we saw in male Tg21-407 mice but not in female Tg21-mice, and can only be seen in female mice after ovariectomy. These 408 findings on activity associated with elevated EPO without increased EPO stimulated 409 erythropoiesis reveal a previously unrecognized EPO function in the brain that controls 410 metabolism via central and peripheral action. approval. Body composition, glucose tolerance, food intake, activity, hematocrit and serum 428 cytokine levels were assessed, and select tissues were harvested for gene and protein expression 429 levels. 430
Immunofluorescence: 431
Anesthetized mice were perfused with saline and 4% paraformaldehyde in 100 mM 432 phosphate buffer, and brains were dissected, postfixed in the same fixative overnight (4°C), and 433 immersed successively in 10%, 20%, 30% sucrose for three consecutive nights (4°C). Under isoflurane anesthesia, each mouse received a cannula (Brain Infusion Kit 3, Alzet, 460
Cupertino, CA) implanted over the appropriate stereotaxic coordinates: midline: 1.00 mm, 461 anterioposterior: 0.34 mm, dorsoventral: 2.30 mm. The cannula was fixed onto the skull with 462 dental cement and connected via polyethylene tubing to a subcutaneously implanted 14-day 463 osmotic minipump (Alzet, model 2006). Minipumps were filled with either recombinant human 464 EPO (Epogen, Amgen, Thousand Oaks, CA) or saline. 465
Body composition and Glucose Tolerance Test (GTT): 466
Body weight was measured using the same balance by the same person. Body 467 composition for fat mass and lean mass were measured using EchoMRI 100H instrument (Echo 468
Medical Systems, Houston, TX) in conscious, immobilized mice. For GTT, mice fasted 469 overnight were injected with glucose (2.0 g/kg). Blood glucose levels were measured before (0 470 minute) and up to 120 minutes after injection from tail vein bleeds (Alphatrak 2 glucometer; 471
Zoetis, Parsippany, NJ). For determination of insulin secretion in response to glucose 472 stimulation, 30 l of blood was collected before (0 min) and after 120 minutes of glucose 473 stimulation; serum was prepared, and flash frozen in liquid nitrogen for later assessment. 474
Food intake, activity, and energy expenditure: 475
Mice were allowed to adapt to individual housing for two weeks and food and water were 476 provided ad libitum. Food intake was then measured for 3 weeks. Energy expenditure was 477 calculated using the energy balance method previously described (79). In brief, caloric energy 478 intake was calculated from food intake and change in body energy stores were calculated at 9.4 479 kcal/gm of body fat and 1.0 kcal/gm of fat-free mass. Energy expenditure was determined as the 480 difference of caloric energy intake and sum of change in body energy store. 
Ovariectomy: 498
Bilateral ovaries were removed from female mice aged 11 weeks as previously described 499 (18). Sham surgery was also carried out in age-matched mice. Animals were allowed one week 500 for recovery and depletion of endogenous estrogen in ovariectomized mice, and then placed on 501 HFD from age 12 weeks to 18 weeks. (D) and female (E) age-matched (5 months) Tg21-and WT-mice during NCD or after 1 month or 598 3 months of HFD-feeding. (F-G) Fat mass vs serum adiponectin levels in male (F) and female 599 (G) age-matched (5 months) Tg21 and WT mice during NCD or after 3 months of HFD-feeding. 600
Box and whisker plots denote bounds ranging from 25 th to 75 th percentile, line represents the 601 median, whiskers ranging from minimum to maximum values, and includes outliers. Statistical Table 1 . Fat mass and serum adiponectin levels in male and female WT-and Tg21-mice. Fat 642 mass and serum adiponectin levels in male and female age-matched (5 months) Tg21-and WT-643 mice during NCD or after 3 months of HFD-feeding (n= 6-8/ group). Numbers represent mean + 644 S.D. and statistical significance was tested by 2-way ANOVA and significant p-values are shown 645 Table 1 : Fat mass and serum adiponectin levels in male and female WT-and Tg21mice Table 1 . Fat mass and serum adiponectin levels in male and female age-matched (5 months) Tg21and WT-mice during NCD or after 3 months of HFD-feeding (n=6-8/group). Numbers represent mean ± S.D. and statistical significance was tested by 2-way ANOVA and significant p-values are shown as bold, italicized. Table 1 . Fat mass and serum adiponectin levels in male and female age-matched (5 months) Tg21and WT-mice during NCD or after 3 months of HFD-feeding (n=6-8/group). Numbers represent mean ± S.D. and statistical significance was tested by 2-way ANOVA and significant p-values are shown as bold, italicized. 
